Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cb21 Pharma S R O is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units, showing that the company's intellectual property is being reviewed by different specialized groups. The prosecution involves distinct examiners, with each reviewer handling a pending case. This distribution within the Biotechnology & Pharmaceuticals sector indicates a diversified approach to patent acquisition that requires tailored legal arguments.
ATKINSON, JOSHUA ALEXANDER is the busiest examiner for the portfolio, currently overseeing 1 pending office action. With 2 pending office actions distributed across 2 distinct art units, the legal strategy must be adapted to the specific procedural expectations of the assigned personnel. This structure suggests that the company is pursuing multiple technical paths that fall under different administrative jurisdictions. Practitioners should monitor the feedback from the distinct examiners to ensure a cohesive strategy across the entire portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693399 | CANNABINOID FORMULATION FOR ORAL ADMINISTRATION | ATKINSON, JOSHUA ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027229 | PHARMACEUTICAL COMPOSITION | LEE, ANDREW P | 100d overdue |
| 18693399 | CANNABINOID FORMULATION FOR ORAL ADMINISTRATION | ATKINSON, JOSHUA ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693399 | CANNABINOID FORMULATION FOR ORAL ADMINISTRATION | ATKINSON, JOSHUA ALEXANDER | 1612 | §102§103§112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18027229 | PHARMACEUTICAL COMPOSITION | LEE, ANDREW P | 1691 | §103 | Final Rejection | 100d overdue | Pending | Mar 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial